Intra-Cellular Therapies Inc [ITCI] stock is trading at $126.20, down -0.05%. An important factor to consider is whether the stock is rising or falling in short-term value. The ITCI shares have gain 33.02% over the last week, with a monthly amount glided 48.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on September 06, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $92 from $68. Previously, Robert W. Baird started tracking the stock with Outperform rating on January 03, 2024, and set its price target to $83. On December 11, 2023, TD Cowen initiated with a Outperform rating and assigned a price target of $75 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $80 on April 20, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $49 on August 22, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $74. In a note dated June 14, 2022, UBS initiated an Buy rating and provided a target price of $75 on this stock.
Intra-Cellular Therapies Inc [ITCI] stock has fluctuated between $62.78 and $128.00 over the past year. Currently, Wall Street analysts expect the stock to reach $104.25 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $126.20 at the most recent close of the market. An investor can expect a potential drop of -17.39% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 613.73M for the trailing twelve months, which represents a growth of 39.00%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 126.00 points at the first support level, and at 125.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 126.57, and for the 2nd resistance point, it is at 126.94.
Ratios To Look Out For
For context, Intra-Cellular Therapies Inc’s Current Ratio is 7.66. On the other hand, the Quick Ratio is 7.51, and the Cash Ratio is 2.8. Considering the valuation of this stock, the price to sales ratio is 21.85, the price to book ratio is 11.68.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman and CEO, that happened on Dec 04 ’24 when 51000.0 shares were sold. Chairman and CEO, Mates Sharon completed a deal on Dec 05 ’24 to sell 51697.0 shares. Meanwhile, Officer Mates Sharon bought 51697.0 shares on Dec 05 ’24.
